Linda Penn, University of Toronto

Research

Dipyridamole Fda Approved Drugs Mevalonate Pathway Prostate Cancer Statins Tumour Metabolism Srebp Transcription Factor Cancer Therapeutics

Latest papers

The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer.
European urology focus · 2021
The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study.
Prostate cancer and prostatic diseases · 2020
Role of Pirh2 in mediating the regulation of p53 and c-Myc.
PLoS genetics · 2011

All 4 publications

Latest funding

Characterization of MYC:R-Loop Interactions in Cancer
CIHR · 2021 · Supervisor
$105,000
Targeting the Metabolic Mevalonate Pathway as an Actionable Prostate Cancer Vulnerability
CIHR · 2021 · Nominated PI
$1,002,150
Molecular drivers of the drug tolerant persister state in patient-derived colorectal cancer models
CIHR · 2020 · Co-investigator
$960,075

All 17 grants and awards

4 publications.

01

The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer.

Goldberg H, Mohsin FK, Saskin R, Kulkarni GS, Berlin A, Kenk M, Wallis CJD, Klaassen Z, Chandrasekar T, Ahmad AE, Sayyid RK, Saarela O, Penn L, Alibhai SMH, Fleshner N

European urology focus2021

DOI: 10.1016/j.euf.2020.06.005 PMID: 32620539

02

The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study.

Goldberg H, Mohsin FK, Saskin R, Kulkarni GS, Berlin A, Kenk M, Wallis CJD, Chandrasekar T, Klaassen Z, Saarela O, Penn L, Alibhai SMH, Fleshner N

Prostate cancer and prostatic diseases2020

DOI: 10.1038/s41391-020-0248-9 PMID: 32641738

03

Role of Pirh2 in mediating the regulation of p53 and c-Myc.

Hakem A, Bohgaki M, Lemmers B, Tai E, Salmena L, Matysiak-Zablocki E, Jung YS, Karaskova J, Kaustov L, Duan S, Madore J, Boutros P, Sheng Y, Chesi M, Bergsagel PL, Perez-Ordonez B, Mes-Masson AM, Penn L, Squire J, Chen X, Jurisica I, Arrowsmith C, Sanchez O, Benchimol S, Hakem R

PLoS genetics2011

DOI: 10.1371/journal.pgen.1002360 PMID: 22125490

04

Oxygen regulation of arterial smooth muscle cell proliferation and survival.

Ray JB, Arab S, Deng Y, Liu P, Penn L, Courtman DW, Ward ME

American journal of physiology. Heart and circulatory physiology2008

DOI: 10.1152/ajpheart.00587.2007 PMID: 18055518

Characterization of MYC:R-Loop Interactions in Cancer

SupervisorCIHR2021Doctoral Research Award: Canada Graduate Scholarships

Principal investigators: Lin, Chien-feng

Keywords: Bioid; Crispr Screen; Myc; R-Loops; Topoisomerase I

$105,000

Targeting the Metabolic Mevalonate Pathway as an Actionable Prostate Cancer Vulnerability

Nominated PICIHR2021Project Grant

Principal investigators: Penn, Linda Z

Keywords: Dipyridamole; Fda Approved Drugs; Mevalonate Pathway; Prostate Cancer; Srebp Transcription Factor; Statins; Tumour Metabolism

$1,002,150

Molecular drivers of the drug tolerant persister state in patient-derived colorectal cancer models

Co-investigatorCIHR2020Project Grant

Principal investigators: O'Brien, Catherine A

Keywords: Autophagy; Chemotherapy; Cholesterol Efflux; Colorectal Cancer; Drug Tolerant Persisters; Lxr, Abca1, Abcg1; Minimal Residual Disease; Mtor; Patient Derived Xenografts; Xenograft

$960,075

Regulating MYC Oncoprotein Stability as an Anti-Cancer Strategy

Nominated PICIHR2017Project Grant

Principal investigators: Penn, Linda Z

Keywords: Cancer Therapeutics; Fluorescence; High Content Analysis; Mass Spectrometry; Myc Oncoprotein; Phosphatases; Protein Turnover; Short Half-Life Proteins; Structure Function Analysis; Transformation

$875,925

Integrated Nanotechnology and Biomedical Sciences Laboratory

Co-investigatorCIHR2017Foundation Grant

Principal investigators: Chan, Warren C

Keywords: Cancer; Nanotechnology

$2,100,092

Targeting mevalonate and sterol metabolism to delay prostate cancer progression

SupervisorCIHR2016Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Longo, Joseph

Keywords: Drug Repurposing; Mevalonate Pathway; Prostate Cancer; Statins; Sterol Metabolism; Tumour Metabolism

$105,000

Targeting the Mevalonate Pathway and its Restorative Feedback Loop

Nominated PICIHR2015Operating Grant

Principal investigators: Penn, Linda Z

Keywords: Dipyridamole; Fda Approved Drugs; Mevalonate Pathway; Prostate Cancer; Rnai Technology; Statins; Tumour Metabolism

$731,950

Nanoparticle-based anti-Myc cancer therapeutics

Co-investigatorNSERC2014Collaborative Health Research Projects

Principal investigators: Shin, Jumi

$448,039

CRC Tier 1

Nominated PICIHR2013Canada Research Chairs - CIHR Funded - Tier 1

Principal investigators: Penn, Linda Z

Keywords: Crc

$1,400,000

Nanoparticle-based anti-Myc cancer therapeutics

Principal investigatorCIHR2013Collaborative Health Research Projects (NSERC partnered)

Principal investigators: Shin, Jumi; Chan, Warren C; Penn, Linda Z

Keywords: Anti-Cancer Therapeutics; B1h; Chip & Chip-Chip; Enhancer Box (E-Box); Mammalian Cell Lines; Myc-Dependent Transformation; Myc/Max Transcription Factors; Nanotechnology & Nanodelivery; Protein Design & Directed Evolution; Protein:Dna Interactions; Y1h; Y2h

$448,040

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Medical Biophysics
Radiation Oncology/Medical Physics
Biostatistics Division
Department of Medical Biophysics
Rheumatology
Department of Pharmacology and Toxicology
Other

Applying for

Paper to mentionMention their CIHR grant from 2021

Subject: Prospective PhD student: Dipyridamole Dear Professor Penn, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer." (2021), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Targeting the Metabolic Mevalonate Pathway as an Actionable Prostate Cancer Vulnerability" (2021), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]